Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Supernus Pharmaceuticals (0LB2) Price & Analysis

0LB2 Stock Chart & Stats

$42.77$1.51(3.66%)
At close: 4:00 PM EDT
$40$453 Aug17 Aug28 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
$42.15 - $43.62
52-Week Range
$37.96 - $59.74
Previous Close
$41.26
Volume
1
Average Volume (3M)
105
Market Cap
$2.44B
Enterprise Value
$2.24B
Total Cash (Recent Filing)
$359.46M
Total Debt (Recent Filing)
$36.20M
Price to Earnings (P/E)
―
Beta
0.47
Next Earnings
Mar 02, 2027
EPS Estimate
1.03
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Broad Product Growth

Strong growth across multiple marketed CNS products indicates broadening commercial traction rather than dependence on one brand. Continued prescription, patient, and revenue expansion can support durable scale, improve operating leverage, and provide resources for pipeline investment.

ONAPGO Exclusivity

Seven years of orphan-drug exclusivity strengthens ONAPGO’s competitive position in a specialized Parkinson’s market. The regulatory protection can support commercial durability, preserve access to the opportunity, and improve the product’s ability to contribute recurring revenue over several years.

Financial Resilience

Very low leverage and positive free cash flow give Supernus meaningful financial flexibility. This supports continued investment in marketed products and pipeline programs, while reducing balance-sheet pressure if earnings remain volatile or the company needs to fund strategic opportunities.

Bears Say

Persistent Net Losses

The continued nine-month GAAP loss shows that strong product revenue has not yet translated into consistent bottom-line profitability. Persistent losses can constrain retained capital, reduce earnings quality, and make future performance more dependent on expense control and successful commercial execution.

Rising Operating Expenses

Higher operating expenses are absorbing more of the company’s growing revenue base and contribute to the ongoing GAAP loss. Unless commercial growth continues to outpace spending, elevated R&D and SG&A could limit margin expansion and weaken the conversion of sales into durable earnings.

Delayed Pipeline Catalyst

A likely 2028 SPN-817 readout extends the time before the program can provide meaningful clinical or commercial validation. Slow recruitment delays potential pipeline contribution, leaves longer exposure to development uncertainty, and increases reliance on existing products for nearer-term growth.

Supernus Pharmaceuticals News

0LB2 FAQ

What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest share price was $37.96 and its highest was $59.74 in the past 12 months.
What is Supernus Pharmaceuticals’s market cap?
Supernus Pharmaceuticals’s market cap is $2.44B.
When is Supernus Pharmaceuticals’s upcoming earnings report date?
Supernus Pharmaceuticals’s upcoming earnings report date is Mar 02, 2027 which is in 121 days.
How were Supernus Pharmaceuticals’s earnings last quarter?
Supernus Pharmaceuticals released its earnings results on Oct 29, 2026. The company reported $0.922 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.432.
Is Supernus Pharmaceuticals overvalued?
According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued.
Does Supernus Pharmaceuticals pay dividends?
Supernus Pharmaceuticals pays a Notavailable dividend of $0.285 which represents an annual dividend yield of ―. See more information on Supernus Pharmaceuticals dividends here
What is Supernus Pharmaceuticals’s EPS estimate?
Supernus Pharmaceuticals’s EPS estimate is 1.03.
How many shares outstanding does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals has 58,235,718 shares outstanding.
What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
Supernus Pharmaceuticals reported an EPS of $0.922 in its last earnings report, beating expectations of $0.49. Following the earnings report the stock price went up 3.66%.
Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0LB2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology